Clinical trial
Multicenter, Open, Randomized Study With Active Control to Evaluate the Early Bactericidal Activity, Safety and Pharmacokinetics of the Drug PBTZ169 When Used in Patients With First-diagnosed Tuberculosis of the Respiratory System With Bacterial Excretion and Saved Bacterial Susceptibility to Isoniazid and Rifampicin
NCT03334734 is registered in ClinicalTrials.gov with Nearmedic Plus LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Open, Randomized Study With Active Control to Evaluate the Early Bactericidal Activity, Safety and Pharmacokinetics of the Drug PBTZ169 When Used in Patients With First-diagnosed Tuberculosis of the Respiratory System With Bacterial Excretion and Saved Bacterial Susceptibility to Isoniazid and Rifampicin
- Lead sponsor
- Nearmedic Plus LLC
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 16, 2016
- Completion date
- February 22, 2018
- Enrollment
- 16 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.